MANAGEMENT STRATEGIES FOR OF CIRRHOTIC CARDIOMYOPATHY.
Article Sidebar
Main Article Content
Abstract
Although considerable progress has been achieved in understanding liver cirrhosis (LC), it continues to pose a significant medical and social challenge. The prevalence of chronic liver disease–related disability and mortality is steadily increasing, making it one of the ten leading causes of death worldwide [3]. Enhancing early diagnostic approaches to identify structural and functional cardiac alterations is essential for predicting disease outcomes and optimizing therapeutic as well as surgical management strategies. The ongoing importance of assessing cardiohemodynamic parameters in LC also stems from the need to further refine the diagnostic criteria for cirrhotic cardiomyopathy (CCM), a concept introduced at the 2005 World Congress of Gastroenterologists [2]. CCM refers to cardiac dysfunction in patients with LC, manifested by a blunted contractile response to stress and/or impaired diastolic relaxation, accompanied by characteristic electrophysiological changes in the absence of other underlying heart diseases [4].
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1. Alqahtani, S. A. Cirrhotic cardiomyopathy / S. A. Alqahtani, T. R. Fouad, S. S. Lee // Semin. Liver Dis. – 2008. – Vol. 28. – P. 59–69.
2. American Heart Association Council on the Kidney in Cardiovascular Disease and Council on Peripheral Vascular Disease, American Heart Association, American College of Cardiology Foundation. Cardiac disease evaluation and management among kidney and liver transplantation candidates: a scientifi c statement from the American Heart Association and the American College of Cardiology Foundation: endorsed by the American Society of Transplant Surgeons, American Society of Transplantation, and National Kidney Foundation / K. L. Lentine [et al.] // Circulation. – 2012. – Vol. 126. – P. 617–663.
3. Bayley, T. J. The circulatory changes in patients with cirrhosis of the liver at rest and during exersize / T. J. Bayley, N. Segel, J. M. Bishop // Clin. Sci. – 1964. – Vol. 26. – P. 227–235.
4. Cardiac alterations in cirrhosis: reversibility after liver transplantation / M. Torregrosa [et al.] // J. Hepatol. – 2005. – Vol. 42. – P. 68–74.
5. Cardiac and proinfl ammatory markers predict prognosis in cirrhosis / S. Wiese [et al.] // Liver Int. – 2014. – Vol. 34. – P. e19–e30.
6. Cardiac dysfunction during liver transplantation: incidence and preoperative predictors / C. Ripoll [et al.] // Transplantation. – 2008. – Vol. 85. – P. 1766–1772. 12. Cardiac dysfunction in cirrhosis is not associated with the severity of liver disease / M. Merli [et al.] // Eur. J. Int. Med. – 2013. – Vol. 24. – P. 172–176.
7.Matsumori A. Hepatitis C virus infection and cardiomyopathies. Circ Res 96: 2005; 96: 144. 8.Поражения сердца при инфекционных болезнях / Ю.П. Финогеев [и др.]. – СПб: Фолиант, 2003. – 251 с.